RVMD · Healthcare · Biotechnology
Revolution Medicines’ 60% quarter still commands a premium, but biotech volume is not confirming the move
RVMD added 3.1% in the latest week and remains close to its 52-week high, but participation was below average and Relative Strength has cooled over four weeks.